Cenegermin

Cenegermin, sold under the brand name Oxervate, also known as recombinant human nerve growth factor, is a recombinant form of human nerve growth factor.^[4] Cenegermin is a peripherally selective agonist of the tropomyosin receptor kinase A (TrkA) and low-affinity nerve growth factor receptor (p75NTR).^[4]

Cenegermin

Clinical data
Trade names	Oxervate
Other names	Recombinant human nerve growth factor; rhNGF, cenegermin-bkbj
AHFS/Drugs.com	Monograph
MedlinePlus	a619001
License data	US DailyMed: Cenegermin
Pregnancy category	AU: B3
Routes of administration	Ophthalmic
ATC code	S01XA24 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)[1][2] CA: ℞-only / Schedule D[3] US: ℞-only[4] EU: Rx-only[5]
Identifiers
CAS Number	1772578-74-1
DrugBank	DB13926
ChemSpider	None
UNII	B6E7K36KT8
KEGG	D11028
Chemical and physical data
Formula	C583H908N166O173S8
Molar mass	13267.15 g·mol−1

The most common side effects include eye pain and inflammation, increased lacrimation (watery eyes), pain in the eyelid and sensation of a foreign body in the eye.^[5]

It was approved for medical use in the European Union in July 2017,^[5] and in the United States in 2018.^[4][6] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.^[6]

Medical uses

Cenegermin is indicated for the treatment of neurotrophic keratitis.^[4][5]

Society and culture

Names

Cenegermin is the international nonproprietary name.^[7] It is also known as human beta-nerve growth factor (beta-NGF)-(1-118) peptide (non-covalent dimer) produced in Escherichia coli.^[7]

Cenegermin is sold under the brand name Oxervate.^[4][5]